Skip to main content
For US Healthcare Professionals
Prescribing Information
For US healthcare professionals only.

Utility Nav

Important Safety Information Prescribing Information Patient Site Enrollment Form Request Ionis Specialist
DAWNZERA (donidalorsen) 80mg Injection Logo

Main navigation

  • Home
    • Efficacy
    • Switch Data
    • Patient-Reported Outcomes
    • Safety
    • Dosing
    • Switch Protocol
  • MOA
    • Starting Patients
    • Ionis Every Step™
  • Resources
  • HAE Impact
  • Important Safety Information Prescribing Information Patient Site Enrollment Form Request Ionis Specialist
    Terms of Use Privacy Policy Consumer Health Data Privacy Policy Your Privacy Choices Contact Us Report Adverse Events Sitemap

Sitemap

Main navigation

  • Home
    • Efficacy
    • Switch Data
    • Patient-Reported Outcomes
    • Safety
    • Dosing
    • Switch Protocol
  • MOA
    • Starting Patients
    • Ionis Every Step™
  • Resources
  • HAE Impact
  • Important Safety Information Prescribing Information Patient Site Enrollment Form Request Ionis Specialist
    Terms of Use Privacy Policy Consumer Health Data Privacy Policy Your Privacy Choices Contact Us Report Adverse Events Sitemap

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.

Ionis Pharmaceuticals logo

Footer

Terms of Use Privacy Policy Consumer Health Data Privacy Policy Your Privacy Choices Contact Us Report Adverse Events Sitemap

DAWNZERA™ is a trademark of Ionis Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. ©2026 Ionis Pharmaceuticals, Inc. US-DONI-2500120 v3.0 10/2026

For healthcare professionals

This website is intended for healthcare professionals in the United States only. Are you a US healthcare professional?

No, go to the patient site

IMPORTANT SAFETY INFORMATION & INDICATION

CONTRAINDICATIONS

DAWNZERA is contraindicated in patients with a history of serious hypersensitivity reactions, including anaphylaxis, to donidalorsen or any of the excipients in DAWNZERA.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with DAWNZERA. If signs and symptoms of serious hypersensitivity reactions occur, discontinue DAWNZERA and institute appropriate therapy.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥ 5%) are injection site reactions, upper respiratory tract infection, urinary tract infection, and abdominal discomfort.

INDICATION

DAWNZERA (donidalorsen) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information for DAWNZERA.